| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |